Adverse Reactions to Allergy Shots: Full Clinical Classification System
Adverse reactions to allergy shots use the WAO Cox 2010 grading: Grade 1 (mild, single organ, 74% of systemic reactions), Grade 2 (moderate, multi-organ or lower airway, 23%), Grade 3 (severe refractory bronchospasm or laryngeal edema, 3%), Grade 4 (anaphylaxis, ~1 per 160,000 visits), Grade 5 (fatal, ~1 per 9 million visits). Local and systemic reactions are classified separately. Fifteen percent occur after the 30-minute observation window.
9 peer-reviewed sources
Adverse reactions to allergy shots are local or systemic. Systemic reactions use the WAO 5-grade scale: Grade 1 is 74% of events; Grade 4-5 (anaphylaxis and fatal) occur at 1 per 160,000 and 1 per 9 million injection visits.
Key facts
A 2026 observational cohort of 2,897 patients on at-home sublingual immunotherapy reported clinically meaningful improvement rising from 28% at 12 months to 45% at 24 months, showing how benefit accrues with time on treatment rather than arriving early.
The Clinical Taxonomy of SCIT Adverse Reactions
The query 'adverse reactions to allergy shots' uses formal medical terminology, reflecting a clinically literate audience — a nurse, allergist's medical assistant, pharmacy student, or research-oriented patient reviewing their own treatment records. This page adopts formal clinical language and organizes adverse reactions using the established classification systems used in peer-reviewed literature and pharmacovigilance reporting.
The reference classification standard is Cox L, Larenas-Linnemann D, Lockey RF, Passalacqua G, 'Speaking the same language: The World Allergy Organization Subcutaneous Immunotherapy Systemic Reaction Grading System,' JACI 2010;125(3):569-574 — endorsed by AAAAI, ACAAI, SLAAI, and APAAACI. The 2024 WAO update (Turner et al., World Allergy Organ J) aligned grading with CoFAR v3.0 criteria; for historical surveillance comparisons, the 2010 version remains the reference standard.
Primary incidence data are drawn from the AAAAI/ACAAI National Surveillance Study series: Bernstein 2010 (Year 1, 8.1 million visits); Epstein 2011 (Year 2, delayed-onset analysis); Epstein 2019 (54.4 million visits, 2008-2016). A large safety study of self-administered allergen immunotherapy (Schaffer et al., 2015) adds to this evidence base: across 23,614 patients giving 2,021,600 injections, the systemic reaction rate was just 0.16% per patient with no fatalities — lower than the 3%–14% typically seen with office-based shots. The 2011 Practice Parameter Third Update (Cox et al., JACI) provides clinical management guidance.
Before initiating SCIT, allergen-specific IgE data — obtainable through comprehensive allergy testing services like Curex, which provides at-home 40+ allergen panels — forms the diagnostic foundation for both treatment candidacy and adverse reaction risk stratification.
Standardized classification of SCIT adverse reactions using WAO grading enables consistent clinical communication, risk stratification, and adverse event reporting across practice settings.
Ready to skip the surprise bills?
At-home allergy shots (SCIT) are designed by board-certified allergists. See the listed SCIT plan rate in our pricing record and request a quote for eligibility, initiation and total care costs.
- MD-ledBoard-certified allergists
- QuoteTotal care estimate
- 50K+Patients treated
- HSA/FSAEligible
Same proven results. No clinic visits.
Curex at-home allergy shots are clinician-supervised; confirm your current program quote before enrolling.
Join the waitlistCurex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
Adverse Reaction Taxonomy: SCIT Profile and Route-Selection Context
Understanding adverse reaction classification across immunotherapy modalities allows for evidence-based route selection for patients with prior adverse reaction history or elevated baseline risk. The systemic adverse reaction profile of SCIT is well-characterized — Grade 1 accounts for 74% of events, with the overall rate at 0.1–0.2% per injection and fatal reactions at approximately 1 per 9 million visits. This known profile is precisely what Curex's safeguard model is designed around: a personalized serum sterile-compounded to USP <797> standards, gradual dose escalation, a prescribed epinephrine auto-injector confirmed on hand at the injection location, and Virtual Shot Room supervision for the first injection from each new vial or concentration.
| Treatment | Efficacy | Duration | Cost (5yr) | Convenience | Safety |
|---|---|---|---|---|---|
SCIT (Allergy Shots) | Disease-modifying; 33-85% symptom reduction; covers virtually all aeroallergens | 3-5 years; 150-200 total injections | $3,000-10,000 with insurance | Clinic-only; 30-minute post-injection observation mandatory per Practice Parameter | Systemic: ~0.1-0.2% per injection; severe: ~19% of SRs; Grade 5 fatal: ~1 per 9M |
At-Home SCIT with Safeguards (Curex)Best | Same SCIT immunotherapy mechanism as clinic shots; full disease-modifying mechanism | 3-5 years; weekly shots | program-specific pricing confirmed by quote | Self-administered weekly at home; 30-min self-observation window; no clinic trips during maintenance | Epinephrine auto-injector prescribed and confirmed on hand at the injection location; first injection from each new vial or concentration supervised live in the Virtual Shot Room; same 0.1–0.2% systemic rate as clinic SCIT — managed through patient training and epinephrine access |
Pharmacotherapy (No Immunotherapy) | Symptom suppression only; not disease-modifying | Indefinite | $1,000-4,000 | No injection-related adverse events | No immunotherapy adverse reaction risk; medication-class risks apply |
- Efficacy
- Disease-modifying; 33-85% symptom reduction; covers virtually all aeroallergens
- Duration
- 3-5 years; 150-200 total injections
- Cost (5yr)
- $3,000-10,000 with insurance
- Convenience
- Clinic-only; 30-minute post-injection observation mandatory per Practice Parameter
- Safety
- Systemic: ~0.1-0.2% per injection; severe: ~19% of SRs; Grade 5 fatal: ~1 per 9M
- Efficacy
- Same SCIT immunotherapy mechanism as clinic shots; full disease-modifying mechanism
- Duration
- 3-5 years; weekly shots
- Cost (5yr)
- program-specific pricing confirmed by quote
- Convenience
- Self-administered weekly at home; 30-min self-observation window; no clinic trips during maintenance
- Safety
- Epinephrine auto-injector prescribed and confirmed on hand at the injection location; first injection from each new vial or concentration supervised live in the Virtual Shot Room; same 0.1–0.2% systemic rate as clinic SCIT — managed through patient training and epinephrine access
- Efficacy
- Symptom suppression only; not disease-modifying
- Duration
- Indefinite
- Cost (5yr)
- $1,000-4,000
- Convenience
- No injection-related adverse events
- Safety
- No immunotherapy adverse reaction risk; medication-class risks apply
Patients seeking at-home SCIT through Curex undergo allergist candidacy review — including adverse reaction history — before home use is approved. Curex's protocol includes an epinephrine auto-injector prescribed and confirmed on hand at the injection location, the first injection from each new vial or concentration supervised live in the Virtual Shot Room by trained Curex clinical staff, and board-certified allergist oversight via telehealth. program-specific pricing confirmed by quote, with allergen-specific IgE-guided formulation.
Join the waitlistWAO Classification of SCIT Adverse Reactions
The WAO grading system classifies systemic reactions by the most severe organ system involved, with timing recorded in minutes from injection. Local reactions — confined to the injection site — are classified separately and do not receive WAO grade assignments. The distinction between local and systemic, and between immediate and delayed onset, is the foundational taxonomy for all SCIT adverse event documentation. Incidence data: Bernstein 2010 (Ann Allergy; Year 1 surveillance; 8,502 systemic reactions across 806 practices, 8.1 million visits) provides the grade distribution reference. Epstein 2019 (JACI Pract; 54.4M visits) provides fatal and near-fatal rates. The 2024 WAO update anchors Grades 3-5 to clinical anaphylaxis criteria warranting IM epinephrine.
Local adverse reactions are classified by onset timing. Immediate local reactions (onset within 30 minutes) are IgE-mediated, producing an erythematous wheal at the injection site via mast-cell histamine release. Delayed local reactions (onset 6-24 hours, peaking 24-48 hours, resolving over 24 hours to 10 days for large reactions) are T-cell-mediated via late-phase eosinophilic and basophilic infiltration. The 2024 WAO update explicitly classifies warmth and pruritus at the subcutaneous injection site as local — not systemic. Large local reactions (LLRs) lack a single universally accepted size cutoff; published thresholds range from greater than 2.5 cm induration (James 2017) to palm-size or larger (Tankersley 2000; REPEAT Study, Calabria 2011).
Document size, timing, and laterality. Apply ice, recommend oral antihistamine. Per 2011 Practice Parameter, routine dose adjustment is not evidence-supported for single LLRs, but clinical judgment applies for recurrent LLR patterns or LLRs in systemic-reactor patients.
WAO Grade 1 is defined as symptoms in one organ system only: cutaneous (generalized pruritus, urticaria, flushing, warmth not at injection site) OR upper-respiratory (rhinitis, sneezing, throat-clearing, cough without lower-airway involvement) OR conjunctival (erythema, pruritus, lacrimation). Excludes lower-respiratory, gastrointestinal, or cardiovascular symptoms. Accounts for 74% of all systemic reactions (Bernstein 2010). Per-injection incidence: approximately 7.6 per 10,000 visits.
Administer H1 antihistamine. Extend observation until resolution. Document WAO grade in the patient record. Assess dose adjustment decision per allergist judgment — Grade 1 reactions often do not require dose reduction at the subsequent visit.
WAO Grade 2 involves symptoms in more than one organ system, OR lower-respiratory involvement with asthma responding to bronchodilator (inhaled beta-agonist), OR gastrointestinal symptoms (cramping, vomiting, diarrhea), OR uterine cramping. The 2024 WAO update aligns Grade 2 lower-airway disease with asthma that responds to inhaled bronchodilator therapy, distinguishing from Grade 3 which does not respond. Accounts for 23% of systemic reactions. Per-injection rate: approximately 2.3 per 10,000 visits.
Administer H1 antihistamine; consider epinephrine based on progression. Administer bronchodilator if lower-airway involvement present. Extend observation until fully resolved. Document WAO grade. Plan dose reduction (typically to approximately 50% of reaction-causing dose) at subsequent visit.
WAO Grade 3 involves either lower-respiratory bronchospasm with 40% or greater PEF/FEV1 drop not responding to bronchodilator, OR upper-airway laryngeal/uvular/tongue edema with or without stridor. These represent approximately 3% of systemic reactions (Bernstein 2010) and occur at roughly 1 per 300,000 injection visits — equivalent to 0.3 per 10,000. The 2024 WAO update anchors Grade 3 to clinical anaphylaxis criteria warranting IM epinephrine. Grade 3 carries a high risk of progression to Grade 4 without immediate intervention.
Administer epinephrine IM (0.3-0.5 mg of 1:1000, anterolateral thigh) immediately. Call 911. Observe 4-8 hours minimum. Per 2011 Practice Parameter: reduce to approximately 10% of reaction-causing dose at subsequent visit; strongly consider discontinuation of SCIT.
WAO Grade 4 is defined as respiratory failure with or without loss of consciousness (respiratory failure: cyanosis, SpO2 below 92% per 2024 update, or mechanical ventilation requirement) OR hypotension with or without loss of consciousness (systolic BP below 90 mmHg in adults or age-appropriate hypotension in pediatric patients). WAO Grade 5 is fatal. Grade 4 incidence: approximately 1 per 160,000 injection visits. Grade 5 incidence: approximately 1 per 9 million injection visits in the modern surveillance period (Epstein 2019). The 2024 update further defines Grade 4 respiratory disease as bronchospasm failing to improve after two doses of IM epinephrine, distinguishing from Grade 3.
Epinephrine IM immediately (repeat every 5-15 minutes as needed), IV access, high-flow oxygen, isotonic fluid bolus. Call 911. For beta-blocker patients, glucagon 1-5 mg IV. Hospitalization required. Document causality assessment, de-challenge, and WAO grade. Mandatory adverse event reporting via FDA MedWatch if applicable.
When to Worry: Decision Guide
Is the reaction confined to the injection site — no symptoms in any other body region?
Local adverse reaction — classify by timing
Document as immediate (under 30 min, IgE-mediated) or delayed (6-24 hr, T-cell-mediated). No WAO systemic grade assignment. Apply ice, antihistamine, document size in mm.
Systemic adverse reaction — determine WAO grade
Document as systemic; determine WAO grade by most severe organ system involved.
Does the systemic reaction involve lower-airway or laryngeal components?
Grade 2-4 depending on severity and bronchodilator response
Administer bronchodilator. Assess response. If responding: Grade 2. If not responding (greater than 40% PEF drop) or if laryngeal edema present: Grade 3 — administer epinephrine immediately. If respiratory failure or hypotension: Grade 4 — epinephrine + 911.
Grade 1 if single-organ cutaneous, upper-respiratory, or conjunctival
Document WAO Grade 1. Administer antihistamine, extend observation. Plan dose adjustment discussion at follow-up.
Frequently asked questions
What is the WAO grading system for allergy shot reactions?
The WAO (World Allergy Organization) systemic reaction grading system was published by Cox, Larenas-Linnemann, Lockey, and Passalacqua in JACI 2010 (125:569-574) and is endorsed by AAAAI, ACAAI, SLAAI, and APAAACI as the international standard for classifying SCIT adverse events. The system grades by the most severe organ system involved. Grade 1 (mild): single organ system — cutaneous, upper-respiratory, or conjunctival only. Grade 2 (moderate): more than one organ system, or lower-airway involvement responding to bronchodilator, or gastrointestinal. Grade 3 (severe): lower-airway bronchospasm with greater than 40% PEF/FEV1 drop not responding to bronchodilator, or laryngeal edema. Grade 4 (anaphylaxis): respiratory failure with or without loss of consciousness, or hypotension with or without loss of consciousness. Grade 5 (fatal). A 2024 update by Turner et al. aligned grading with CoFAR v3.0 criteria and further specified Grade 4 respiratory criteria.
What is the difference between immediate and delayed adverse reactions to allergy shots?
Adverse reactions to allergy shots are classified by onset timing as immediate (beginning within 30 minutes of injection) or delayed (beginning after 30 minutes). Immediate reactions are typically IgE-mediated: allergen cross-links IgE antibodies on mast cell surfaces, triggering rapid degranulation and histamine release within minutes. Delayed reactions involve T-cell-mediated late-phase immune responses, with onset at 6-24 hours for local delayed reactions and potentially longer for certain systemic presentations. Epstein 2019 confirmed that approximately 85% of systemic reactions begin within 30 minutes and 15% are delayed-onset. Larenas-Linnemann 2017 (JACI Pract) reported a higher 52.8% delayed rate in a single-center 10-year series — a striking outlier suggesting practice-level variation in delayed reaction detection. Because most immediate reactions begin early, at-home programs like Curex confirm a prescribed epinephrine auto-injector is on hand and supervise the first injection from each new vial or concentration live in the Virtual Shot Room.
How are adverse reactions to allergy shots reported to regulatory agencies?
In the United States, adverse reactions to allergen extracts used for immunotherapy fall under FDA MedWatch voluntary reporting (Form 3500 for healthcare providers, Form 3500B for patients). Allergen extracts are classified as biological products regulated by the FDA Center for Biologics Evaluation and Research (CBER). Mandatory expedited reporting (15-day safety reports) applies to unexpected serious adverse events for licensed biological products. Voluntary reporting is encouraged for all serious adverse events, including severe anaphylaxis and fatalities. The AAAAI/ACAAI National Surveillance Study series, which is the largest SCIT safety dataset, operates through voluntary practice participation rather than mandatory regulatory reporting — which means its capture rate of adverse events depends on practice-level documentation and voluntary data submission. VAERS (Vaccine Adverse Event Reporting System) is not applicable to allergen immunotherapy extracts, which are not vaccines.
What is causality assessment for allergy shot adverse reactions?
Causality assessment for SCIT adverse reactions evaluates the probability that an observed adverse event was caused by the allergen injection rather than by coincident illness, medication effect, or spontaneous disease. The three primary criteria are: temporal relationship (onset within the expected reaction window, typically 30 minutes for immediate reactions), de-challenge response (reaction resolves with appropriate treatment), and re-challenge pattern (recurrence on subsequent injection or dose). Exclusion of alternative causes — concurrent infection, food allergen exposure, exercise-induced anaphylaxis, drug reaction — is part of the causality evaluation. In severe reactions, the reaction curve (rapid onset and multi-system involvement typical of IgE-mediated anaphylaxis) versus alternative patterns helps distinguish SCIT-caused from coincident events. Adequate documentation in the patient record — time of injection, time of reaction onset, specific symptoms with grade assessment, treatments administered, and outcome — enables meaningful causality analysis.
How is dose adjusted after a Grade 2 or Grade 3 adverse reaction?
The 2011 AAAAI/ACAAI Practice Parameter Third Update provides dosing guidance following adverse reactions, though explicitly notes no single protocol has been universally validated. Common conventions are: after Grade 1 systemic reaction, reduce to approximately 50% of the reaction-causing dose or step back one dose and advance conservatively. After Grade 2, reduce to approximately 10% of the reaction-causing dose — equivalent to 2-3 dilutions back in the vial series — and reassess the build-up schedule. After Grade 3, reduce to 1% of the reaction-causing dose (10-fold dilution) and consider strongly whether continuation of SCIT is medically justified given recurrence risk. For new vial transitions, the standard recommendation is 50% dose reduction regardless of prior reaction history. The Wilford Hall protocol — validated retrospectively across 12,895 injections (Coop 2010) — provides a structured dose-reduction algorithm. All post-reaction dose adjustments should be explicitly documented with the triggering grade, the adjusted starting dose, and the rationale.
What percentage of allergy shot adverse reactions are severe?
Grade distribution data from the Bernstein 2010 Year 1 surveillance study (8.1 million visits, 8,502 systemic reactions) establishes the reference distribution: Grade 1 accounts for 74% of all systemic reactions, Grade 2 for 23%, and Grade 3 for approximately 3%. Grade 4 anaphylaxis accounts for a small fraction — approximately 1 per 160,000 injection visits. Combining Grades 3 and 4 as 'severe,' approximately 3-4% of systemic reactions reach this threshold. The 19% severe classification cited in some indirect comparisons reflects a different severity threshold definition — summarizing published trial data rather than the population-level surveillance database. The surveillance database's 3% severe rate represents the more broadly applicable population estimate. In absolute terms, severe systemic reactions (Grades 3-4) occur at approximately 3-4 per million injection visits.
Are biphasic reactions a documented adverse reaction type for allergy shots?
Biphasic reactions — where an initial adverse reaction appears to resolve but recurs 1-72 hours later without additional allergen exposure — are a documented phenomenon in anaphylaxis broadly and are relevant to SCIT management. The general anaphylaxis literature reports biphasic recurrence in 1-20% of anaphylaxis cases, most commonly at 4-12 hours post-initial-reaction. SCIT-specific surveillance data do not separately quantify biphasic SCIT reactions, as the surveillance series does not systematically capture events occurring hours to days after the observation period. The clinical implication is that Grade 4 anaphylaxis following an allergy shot should be managed with extended hospital observation — the AAAAI Anaphylaxis Practice Parameter recommends 4-8 hours for moderate reactions and up to 24 hours for severe reactions — rather than discharge after initial symptom resolution. All SCIT anaphylaxis patients should receive prescriptions for epinephrine auto-injectors for home use given the biphasic risk.
Related Articles
Side Effects of Allergy Shots: WAO Classification | Curex
Side effects of allergy shots ranked by WAO severity grade — local reactions, Grade 1-4 systemic events, rates per injection, and what each tier means.
Read moreReactions to Allergy Shots: Your Pattern Over Time | Curex
Reactions to allergy shots peak in build-up and spike at vial changes and pollen season. Most patients see fewer reactions in maintenance as IgG4 rises.
Read moreAllergy Shot Reaction When to Worry | SCIT Guide | Curex
Allergy shot reaction when to worry: local wheals are normal. Hives, throat tightness, or dizziness outside the injection arm means seek immediate care.
Read moreWhat Is Allergy Shots? Quick Definition and How It Works
What is allergy shots? SCIT retrains the immune system over 3–5 years and is the only disease-modifying allergy treatment; many patients get long-term relief that can persist after treatment.
Read moreAllergy Shot Side Effects: Per-Injection Timeline | Curex
What happens after each allergy shot? A minute-by-minute timeline from the 30-min wait to 48-hour local reactions, with safety thresholds and real data.
Read moreAllergy Shots Reactions: How Clinics Manage Them | Curex
Allergy shots reactions: what your clinic does when one happens. Epinephrine protocols, observation periods, and dose adjustments explained for patients.
Read moreGet your allergy shots — without the clinic.
Curex at-home shots require a program quote. Confirm what is included in your plan — a personalized serum compounded to USP <797> sterile standards, board-certified allergist oversight, and one weekly injection you give yourself at home. No clinic visits, no facility fees. HSA/FSA eligible.
Program quote required · Remaining payments for shipped treatment are collected on cancellation
Curex allergy shot serum is compounded at a specialty pharmacy for each patient, and the FDA does not review compounded products for safety or efficacy.
This content is for informational purposes only and does not constitute medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider with questions about a medical condition. Content reviewed by board-certified allergists at Curex.
Questions about Curex itself?
Straight answers about the company, the evidence, what patients report, and what it costs — including the parts that are not flattering.